FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200375432> ?p ?o ?g. }

• W4200375432 endingPage "161.e23" @default.
• W4200375432 startingPage "161.e15" @default.
• W4200375432 abstract "To report experience with focal brachytherapy (FB) and compare its clinical outcomes with those of radical prostatectomy (RP) in localized prostate cancer.Fifty-one patients with low- to intermediate-risk prostate cancer underwent low-dose-rate FB. Survival rates free from biochemical failure (BF), additional treatment (AT) including re-FB, and whole-gland or systemic salvage therapy (ST) were calculated and oncological risk factors were investigated. Patient-reported outcomes on genitourinary function were also assessed. Using propensity scoring, 51 pair-matched RP patients were selected. Oncological control, urinary continence, and ejaculation status after FB and RP were compared.During a median 5.7-year follow-up, BF, AT, and ST occurred in 12 (24%), 10 (20%), and 4 FB patients (8%), respectively. 6 of 10 AT patients were managed with re-FB alone. In the RP cohort, 3 patients (6%) underwent ST. 5-year BF-free survival rate after FB was 79%. Compared to 5-year ST-free survival rate of 94% after RP, ST-free and AT-free survival rates after FB were 93% (P = 0.813) and 87% (P = 0.049), respectively. Multivariate analyses of FB-treated patients showed that time to PSA nadir was negatively associated with BF and AT (hazard ratio 0.84 and 0.83, respectively, P <0.001 for each). The difference in oncological outcomes between low- and intermediate-risk categories was not significant. At 2 years after FB and RP, pad-free continence rates were 100% and 81%, respectively (P = 0.001). Ejaculation was preserved in 67% and 0% of patients who had been capable of ejaculation at baseline, respectively (P <0.001).In low- to intermediate-risk prostate cancer, FB-treated patients achieved superior genitourinary function compared to pair-matched RP patients. The need for ST was not substantially different between the 2 treatment cohorts. Over half of patients requiring AT could be managed by re-focal treatment rather than whole-gland ST. Early PSA nadir may predict poor oncological control after FB." @default.
• W4200375432 created "2021-12-31" @default.
• W4200375432 creator A5005409020 @default.
• W4200375432 creator A5015291340 @default.
• W4200375432 creator A5030126202 @default.
• W4200375432 creator A5032348337 @default.
• W4200375432 creator A5039314030 @default.
• W4200375432 creator A5048923727 @default.
• W4200375432 creator A5060240988 @default.
• W4200375432 creator A5074658156 @default.
• W4200375432 creator A5084914638 @default.
• W4200375432 creator A5089503656 @default.
• W4200375432 date "2022-04-01" @default.
• W4200375432 modified "2023-10-04" @default.
• W4200375432 title "Focal brachytherapy for localized prostate cancer: 5.7-year clinical outcomes and a pair-matched study with radical prostatectomy" @default.
• W4200375432 cites W1645597578 @default.
• W4200375432 cites W1965809713 @default.
• W4200375432 cites W1980817456 @default.
• W4200375432 cites W1982311990 @default.
• W4200375432 cites W2015165432 @default.
• W4200375432 cites W2019313566 @default.
• W4200375432 cites W2055178611 @default.
• W4200375432 cites W2084366964 @default.
• W4200375432 cites W2093867637 @default.
• W4200375432 cites W2120768585 @default.
• W4200375432 cites W2154072446 @default.
• W4200375432 cites W2528302844 @default.
• W4200375432 cites W2746722611 @default.
• W4200375432 cites W2769321555 @default.
• W4200375432 cites W2792682686 @default.
• W4200375432 cites W2810125259 @default.
• W4200375432 cites W2965505770 @default.
• W4200375432 cites W2987531956 @default.
• W4200375432 cites W2988160321 @default.
• W4200375432 cites W3026839641 @default.
• W4200375432 cites W3097158220 @default.
• W4200375432 cites W3119966384 @default.
• W4200375432 cites W3125383642 @default.
• W4200375432 cites W3152543644 @default.
• W4200375432 doi "https://doi.org/10.1016/j.urolonc.2021.11.009" @default.
• W4200375432 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34895818" @default.
• W4200375432 hasPublicationYear "2022" @default.
• W4200375432 type Work @default.
• W4200375432 citedByCount "4" @default.
• W4200375432 countsByYear W42003754322022 @default.
• W4200375432 countsByYear W42003754322023 @default.
• W4200375432 crossrefType "journal-article" @default.
• W4200375432 hasAuthorship W4200375432A5005409020 @default.
• W4200375432 hasAuthorship W4200375432A5015291340 @default.
• W4200375432 hasAuthorship W4200375432A5030126202 @default.
• W4200375432 hasAuthorship W4200375432A5032348337 @default.
• W4200375432 hasAuthorship W4200375432A5039314030 @default.
• W4200375432 hasAuthorship W4200375432A5048923727 @default.
• W4200375432 hasAuthorship W4200375432A5060240988 @default.
• W4200375432 hasAuthorship W4200375432A5074658156 @default.
• W4200375432 hasAuthorship W4200375432A5084914638 @default.
• W4200375432 hasAuthorship W4200375432A5089503656 @default.
• W4200375432 hasConcept C121608353 @default.
• W4200375432 hasConcept C126322002 @default.
• W4200375432 hasConcept C126894567 @default.
• W4200375432 hasConcept C133507102 @default.
• W4200375432 hasConcept C141071460 @default.
• W4200375432 hasConcept C207103383 @default.
• W4200375432 hasConcept C2777416452 @default.
• W4200375432 hasConcept C2779466945 @default.
• W4200375432 hasConcept C2780192828 @default.
• W4200375432 hasConcept C44249647 @default.
• W4200375432 hasConcept C509974204 @default.
• W4200375432 hasConcept C71924100 @default.
• W4200375432 hasConcept C72563966 @default.
• W4200375432 hasConceptScore W4200375432C121608353 @default.
• W4200375432 hasConceptScore W4200375432C126322002 @default.
• W4200375432 hasConceptScore W4200375432C126894567 @default.
• W4200375432 hasConceptScore W4200375432C133507102 @default.
• W4200375432 hasConceptScore W4200375432C141071460 @default.
• W4200375432 hasConceptScore W4200375432C207103383 @default.
• W4200375432 hasConceptScore W4200375432C2777416452 @default.
• W4200375432 hasConceptScore W4200375432C2779466945 @default.
• W4200375432 hasConceptScore W4200375432C2780192828 @default.
• W4200375432 hasConceptScore W4200375432C44249647 @default.
• W4200375432 hasConceptScore W4200375432C509974204 @default.
• W4200375432 hasConceptScore W4200375432C71924100 @default.
• W4200375432 hasConceptScore W4200375432C72563966 @default.
• W4200375432 hasIssue "4" @default.
• W4200375432 hasLocation W42003754321 @default.
• W4200375432 hasLocation W42003754322 @default.
• W4200375432 hasOpenAccess W4200375432 @default.
• W4200375432 hasPrimaryLocation W42003754321 @default.
• W4200375432 hasRelatedWork W2014208405 @default.
• W4200375432 hasRelatedWork W2024634086 @default.
• W4200375432 hasRelatedWork W2050896940 @default.
• W4200375432 hasRelatedWork W2067947108 @default.
• W4200375432 hasRelatedWork W2107251918 @default.
• W4200375432 hasRelatedWork W2143699516 @default.
• W4200375432 hasRelatedWork W2280096226 @default.
• W4200375432 hasRelatedWork W2794249056 @default.
• W4200375432 hasRelatedWork W2946095553 @default.
• W4200375432 hasRelatedWork W4213295590 @default.

• next